iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 8, 2010) - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback